Objectives In 2008, we initiated a prospective study to explore the frequency and predictive
value of epidermal growth factor receptor (EGFR) mutations in an unselected population of …

Background The purpose of this study was to evaluate the efficacy of erlotinib as front-line
treatment in clinically selected patients with non–small-cell lung cancer (NSCLC). Patients …

Background Low-dose erlotinib may be as effective as gefitinib or erlotinib at full dose in non-
small cell lung cancer (NSCLC) patients with activating mutations of the epidermal growth …

Purpose The tyrosine kinase inhibitors (TKIs) gefitinib and erlotinib are effective in non-small
cell lung cancers (NSCLCs) with epidermal growth factor receptor (EGFR) gene mutations …

8023 Background: The purpose of the study was to evaluate the efficacy of erlotinib and the
feasibility of screening for EGFR mutations in advanced NSCLC p (chemonaive or relapsed …

PURPOSE: The use of erlotinib after gefitinib failure in patients with non-small cell lung
cancer (NSCLC) is not clearly clarified in clinical practice. We sought to compile the …

Background Activating mutations in the epidermal growth factor receptor gene (EGFR)
confer hypersensitivity to the tyrosine kinase inhibitors gefitinib and erlotinib in patients with …

Background: A phase III trial was conducted to compare the safety and efficacy of erlotinib
with that of gefitinib in advanced non-small cell lung cancer harbouring epidermal growth …

Objective Erlotinib has been reported to be useful for treatment of non-small-cell lung cancer
harboring mutation of the epidermal growth factor receptor gene EGFR-mt. However, no …

The epidermal growth factor receptor (EGFR) mutation is the first recognized molecular
target in non-small cell lung cancer that makes personalized therapy feasible. This …